Anti-PEG10/EDR antibody (ab151782)
Key features and details
- Rabbit polyclonal to PEG10/EDR
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-PEG10/EDR antibody
See all PEG10/EDR primary antibodies -
Description
Rabbit polyclonal to PEG10/EDR -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species WB Human
-
Immunogen
Synthetic peptide corresponding to Mouse PEG10/EDR aa 350-450 conjugated to keyhole limpet haemocyanin.
Database link: Q7TN75 -
Positive control
- This antibody gave a positive signal in the following whole cell lysates: MDA MB 361; HepG2; PC3.
-
General notes
This product was previously labelled as PEG10
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentration
Concentration information loading...Purity
Immunogen affinity purifiedClonality
PolyclonalIsotype
IgGResearch areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab151782 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
GuaranteedTested applications are guaranteed to work and covered by our Abpromise guarantee.
PredictedPredicted to work for this combination of applications and species but not guaranteed.
IncompatibleDoes not work for this combination of applications and species.
Application Species WB HumanAll applications MouseApplication Abreviews Notes WB Use a concentration of 1 µg/ml. Detects a band of approximately 110 kDa (predicted molecular weight: 110 kDa).Notes WB
Use a concentration of 1 µg/ml. Detects a band of approximately 110 kDa (predicted molecular weight: 110 kDa).Target
-
Function
Prevents apoptosis in hepatocellular carcinoma (HCC) cells through interaction with SIAH1, a mediator of apoptosis. May also have a role in cell growth promotion and hepatoma formation. Inhibits the TGF-beta signaling by interacting with the TGF-beta receptor ALK1. When overexpressed, induces the formation of cellular extension, such as filipodia in association with ALK1. Involved at the immediate early stage of adipocyte differentiation (By similarity). May bind to the 5'-GCCTGTCTTT-3' DNA sequence of the MB1 domain in the myelin basic protein (MBP) promoter. -
Tissue specificity
Expressed in the cytotrophoblast layer but not in the overlying syncytiotrophoblast of the placenta. Expressed in prostate and breast carcinomas but not in normal breast and prostate epithelial cells. Expressed in the HepG2 cell line (at protein level). Expressed in brain, liver, spleen, kidney, thymus, lung, ovary, testis, reactive lymph node, skeletal muscle, adipose tissue and placenta. Expressed in pancreatic and hepatocellular carcinomas (HCC). -
Sequence similarities
Contains 1 CCHC-type zinc finger. -
Developmental stage
Expressed in placenta during the first trimester of gestation (at protein level). In placenta, down-regulated at early hypoxic phase, and highly activated at 11-12 week of gestation. -
Post-translational
modificationsIsoform RF1/RF2 undergoes proteolytic cleavage. -
Cellular localization
Nucleus. Cytoplasm. Detected predominantly in the cytoplasm of breast and prostate carcinomas, in hepatocellular carcinoma (HCC) and B-cell chronic lymphocytic leukemia (B-CLL) cells and in the HepG2 cell line. Colocalized with ALK1. - Information by UniProt
-
Database links
- Entrez Gene: 23089 Human
- Entrez Gene: 170676 Mouse
- Omim: 609810 Human
- SwissProt: Q86TG7 Human
- SwissProt: Q7TN75 Mouse
- Unigene: 147492 Human
- Unigene: 320575 Mouse
-
Alternative names
- AA407948 antibody
- Edr antibody
- Embryonal carcinoma differentiation regulated antibody
see all
Images
-
Western blot - Anti-PEG10/EDR antibody (ab151782)All lanes : Anti-PEG10/EDR antibody (ab151782) at 1 µg/ml (Milk blocking - 1%)
Lane 1 : MDA-MB-361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Whole Cell Lysate
Lane 2 : PC3 (Human prostate carcinoma cell line) Whole Cell Lysate Whole Cell Lysate
Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lane 4 : MDA-MB-361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Whole Cell Lysate with Immunising peptide at 1 µg/ml
Lane 5 : PC3 (Human prostate carcinoma cell line) Whole Cell Lysate Whole Cell Lysate with Immunising peptide at 1 µg/ml
Lane 6 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate with Immunising peptide at 1 µg/ml
Lysates/proteins at 25 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 110 kDa
Observed band size: 110 kDa
Additional bands at: 50 kDa (possible non-specific binding), 60 kDa (possible non-specific binding)
Exposure time: 2 minutesThis blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 1% Milk before being incubated with ab151782 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
Datasheets and documents
References (0)
ab151782 has not yet been referenced specifically in any publications.
Images
-
Western blot - Anti-PEG10/EDR antibody (ab151782)All lanes : Anti-PEG10/EDR antibody (ab151782) at 1 µg/ml (Milk blocking - 1%)
Lane 1 : MDA-MB-361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Whole Cell Lysate
Lane 2 : PC3 (Human prostate carcinoma cell line) Whole Cell Lysate Whole Cell Lysate
Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lane 4 : MDA-MB-361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Whole Cell Lysate with Immunising peptide at 1 µg/ml
Lane 5 : PC3 (Human prostate carcinoma cell line) Whole Cell Lysate Whole Cell Lysate with Immunising peptide at 1 µg/ml
Lane 6 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate with Immunising peptide at 1 µg/ml
Lysates/proteins at 25 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 110 kDa
Observed band size: 110 kDa
Additional bands at: 50 kDa (possible non-specific binding), 60 kDa (possible non-specific binding)
Exposure time: 2 minutesThis blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 1% Milk before being incubated with ab151782 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
